<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/39E6A660-94BC-427C-9ACD-28C18EDFA36E"><gtr:id>39E6A660-94BC-427C-9ACD-28C18EDFA36E</gtr:id><gtr:name>Proveca Limited</gtr:name><gtr:address><gtr:line1>DARESBURY INNOVATION CENTRE KECKWICK LANE , DARESBURY</gtr:line1><gtr:city>WARRINGTON</gtr:city><gtr:postCode>WA4 4FS</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39E6A660-94BC-427C-9ACD-28C18EDFA36E" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>39E6A660-94BC-427C-9ACD-28C18EDFA36E</gtr:id><gtr:name>Proveca Limited</gtr:name><gtr:address><gtr:line1>DARESBURY INNOVATION CENTRE KECKWICK LANE , DARESBURY</gtr:line1><gtr:city>WARRINGTON</gtr:city><gtr:postCode>WA4 4FS</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24342.0</gtr:offerGrant><gtr:projectCost>40570.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AFE0EF89-A983-496A-8188-2A37A54ACE82"><gtr:id>AFE0EF89-A983-496A-8188-2A37A54ACE82</gtr:id><gtr:firstName>Clare</gtr:firstName><gtr:surname>Gleeson</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700200"><gtr:id>77486690-57C7-4A3E-A28B-D6BC350492AE</gtr:id><gtr:title>Novel age-appropriate paediatric formulations for the treatment of epilepsy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700200</gtr:grantReference><gtr:abstractText>Epilepsy has a high prevalence and impacts 0.5% to 1% of the paediatric population. In the
UK there are an estimated 60,000 children under 18 with epilepsy. The estimated number of
children and adolescents in Europe with active epilepsy is 0.9 million. Up to 30% of children
still do not respond adequately to current drug therapies.
Rather than relying on anecdote, case reports or open studies of clinical experience, drug
choice in childhood epilepsy should be evidence-based as in adults. However, there are few
randomised controlled trials on which to base drug choice within the epilepsy syndromes.
With extemporaneous preparations or off-label prescriptions, the amount of active ingredient
for AED received by the patient can vary as much as 20%. Conversely, a 10% decrease in
AED concentration is enough to cause a previously seizure-free patient to suffer a
breakthrough seizure, which has considerable consequences such as injury or death to the
patient or emotional distress.
The objective for Proveca is to develop a portfolio of licensed age appropriate formulations of
off-patent medicines (those not covered by a patent or supplementary certificate) for the
treatment of epilepsy in children.
Proveca will conduct a Proof of Market research to understand which of off-patent
antiepileptic drug (AED) candidates should be prioritised for Proof of Concept and clinical
trials and subsequently apply for a Paediatric Use Marketing Authorisation (PUMA), the tool
identified by the EMA to bridge the gap for off-patent drugs.</gtr:abstractText><gtr:fund><gtr:end>2013-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24342</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700200</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>